The PATRICIA Phase II trial tested the combination of palbociclib plus trastuzumab with or without letrozole in advanced HER2+ breast cancer patients who had received at least one prior line of trastuzumab therapy. This evidence concerns the gene ERBB2 and breast carcinoma.